These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38967654)

  • 1. Developing expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome.
    Lukowiak TM; Cahn B; Samie F; Leffell DJ; Oro A; Kibbi N; Kheterpal M; Babakoohi S; Khushalani NI; Stephenson A; Ma MS; Shi VJ; Ahmed A; Koza E; Haq M; Yi MD; Nadir U; Yoo S; Brieva JC; Lucas J; Haber R; Alam M
    Arch Dermatol Res; 2024 Jul; 316(7):453. PubMed ID: 38967654
    [No Abstract]   [Full Text] [Related]  

  • 2. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
    Wolfe CM; Green WH; Cognetta AB; Hatfield HK
    Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
    Lear JT
    N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
    Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
    N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 6. Enlarging Multiple Neoplastic Skin Growths.
    Feinstein EG; Zhou M; Setabutr P
    JAMA Ophthalmol; 2016 Mar; 134(3):337-8. PubMed ID: 26767432
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
    Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
    Chang AL; Atwood SX; Tartar DM; Oro AE
    JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114
    [No Abstract]   [Full Text] [Related]  

  • 10. Acquisition of Drug Resistance in Basal Cell Nevus Syndrome Tumors through Basal to Squamous Cell Carcinoma Transition.
    Jussila AR; Haensel D; Gaddam S; Oro AE
    J Invest Dermatol; 2024 Jun; 144(6):1368-1377.e6. PubMed ID: 38157930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatments and signaling pathway inhibitors.
    Tang JY; Marghoob AA
    Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S14-8. PubMed ID: 22177102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Rheumatoid Arthritis Developing in Conjunction with Gorlin Syndrome.
    Scott JF; Bordeaux JS
    J Rheumatol; 2016 Jul; 43(7):1447-9. PubMed ID: 27371652
    [No Abstract]   [Full Text] [Related]  

  • 13. Harnessing hedgehog for the treatment of basal cell carcinoma.
    Harms KL; Dlugosz AA
    JAMA Dermatol; 2013 May; 149(5):607-8. PubMed ID: 23677088
    [No Abstract]   [Full Text] [Related]  

  • 14. Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma.
    Tang JY
    Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S6-9. PubMed ID: 22177103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibitors of the Hedgehog signalling pathway: hope for the treatment of basal cell carcinoma].
    Vidal V
    Med Sci (Paris); 2010 Mar; 26(3):231-3. PubMed ID: 20346268
    [No Abstract]   [Full Text] [Related]  

  • 16. Basal cell carcinoma: hedgehog pathway inhibitors and beyond.
    Walls B
    Cutis; 2013 Jun; 91(6):E1-4. PubMed ID: 23837158
    [No Abstract]   [Full Text] [Related]  

  • 17. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
    Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
    J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
    Ally MS; Wysong A; Tang JY; Aasi S
    Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors.
    Zhu GA; Li AS; Chang AL
    JAMA Dermatol; 2014 Aug; 150(8):877-9. PubMed ID: 24898076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
    Kieny A; Kremer V; Scheidecker S; Lipsker D
    Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.